Potential benefit of omalizumab in respiratory diseases

Annals of Allergy, Asthma and Immunology

Volumn 113, Issue 5, 2014, Pages 513-519

  Bonini, Matteo ^a   Di Maria, Giuseppe ^b   Paggiaro, Pierluigi ^c   Rossi, Andrea ^d   Senna, Gianenrico ^d   Triggiani, Massimo ^e   Canonica, Giorgio Walter ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d University and General Hospital   (Italy)

^e UNIVERSITY OF SALERNO   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; ANTI-IGE ANTIBODIES; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC ASTHMA; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC RHINITIS; BLOOD LEVEL; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FUNCTIONAL ASSESSMENT; HAY FEVER; HUMAN; LUNG FUNCTION; MEDICAL RESEARCH; NOSE POLYP; OUTCOME ASSESSMENT; PERENNIAL RHINITIS; RESPIRATORY TRACT DISEASE; REVIEW; SCORING SYSTEM; SENSITIVITY ANALYSIS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASES;

ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT DISEASES;

EID: 84913540442     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2014.06.031     Document Type: Review

References (62)

1. J.B. Bice, E. Leechawengwongs, and A. Montanaro Biologic targeted therapy in allergic asthma Ann Allergy Asthma Immunol 112 2014 108 115
2. S.T. Holgate, R. Djukanović, T. Casale, and J. Bousquet Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy Clin Exp Allergy 35 2005 408 416
3. V. Siroux, M.P. Oryszczyn, and E. Paty Relationships of allergic sensitization, total immunoglobulin E and blood eosinophils to asthma severity in children of the EGEA Study Clin Exp Allergy 33 2003 746 751
4. R. Normansell, S. Walker, S.J. Milan, E.H. Walters, and P. Nair Omalizumab for asthma in adults and children Cochrane Database Syst Rev 1 2014 CD003559
5. G. Norman, R. Faria, and F. Paton Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation Health Technol Assess 17 2013 1 342
6. J. Corren, T.B. Casale, B. Lanier, R. Buhl, S. Holgate, and P. Jimenez Safety and tolerability of omalizumab Clin Exp Allergy 39 2009 788 797
7. J.V. Fahy, H.E. Fleming, and H.H. Wong The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects Am J Respir Crit Care Med 155 1997 1828 1834
8. T.A. Borkowski, M.H. Jouvin, S.Y. Lin, and J.P. Kinet Minimal requirements for IgEmediated regulation of surface Fc epsilon RI J Immunol 167 2001 1290 1296
9. J.T. Schroeder, A.P. Bieneman, and K.L. Chichester Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization J Allergy Clin Immunol 125 2010 896 901.e6
10. P. Chanez, C. Contin-Bordes, and G. Garcia Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma Respir Med 104 2010 1608 1617
11. T. Bieber The pro- and anti-inflammatory properties of human antigenpresenting cells expressing the high affinity receptor for IgE (Fc epsilon RI) Immunobiology 212 2007 499 503
12. H.S. Chand, M. Schuyler, and N. Joste Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways J Allergy Clin Immunol 125 2010 1157 1158.e5
13. G. Marone, M. Triggiani, and A. de Paulis Mast cells and basophils: friends as well as foes in bronchial asthma? Trends Immunol 26 2005 25 31
14. B. Rogala, and J. Glück The role of interleukin-33 in rhinitis Curr Allergy Asthma Rep 13 2013 196 202
15. J.M. Oliver, C.A. Tarleton, and L. Gilmartin Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy Int Arch Allergy Immunol 151 2010 275 284
16. D.W. Macglashan Jr., and S.S. Saini Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation J Allergy Clin Immunol 132 2013 906 911
17. A.M. Cooper, P.S. Hobson, and M.R. Jutton Soluble CD23 controls IgE synthesis and homeostasis in human B cells J Immunol 188 2012 3199 3207
18. D.J. Maselli, H. Singh, J. Diaz, and J.I. Peters Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study Ann Allergy Asthma Immunol 110 2013 457 461
19. P.J. Gergen, S.J. Arbes Jr., A. Calatroni, H.E. Mitchell, and D.C. Zeldin Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006 J Allergy Clin Immunol 124 2009 447 453
20. J. Corren Asthma phenotypes and endotypes: an evolving paradigm for classification Discov Med 15 2013 243 249
21. R. Halwani, S. Al-Muhsen, and Q. Hamid T helper 17 cells in airway diseases: from laboratory bench to bedside Chest 143 2013 494 501
22. H.Y. Kim, R.H. DeKruyff, and D.T. Umetsu The many paths to asthma: phenotype shaped by innate and adaptive immunity Nat Immunol 11 2010 577 584
23. L.P. de Llano, C. Vennera Mdel, and F.J. Álvarez Effects of omalizumab in nonatopic asthma: results from a Spanish multicenter registry J Asthma 50 2013 296 301
24. G. Garcia, A. Magnan, and R. Chiron A proof of concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma Chest 144 2013 411 419
25. P. Gevaert, L. Calus, and T. Van Zele Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma J Allergy Clin Immunol 131 2013 110 116.e1
26. N. Fuiano, S. Fusilli, G. Passalacqua, and C. Incorvaia Allergen-specific immunoglobulin E in the skin and nasal mucosa of symptomatic and asymptomatic children sensitized to aeroallergens J Investig Allergol Clin Immunol 20 2010 425 430
27. C. Bachert, K. van Steen, and N. Zhang Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma J Allergy Clin Immunol 130 2012 376 381.e8
28. P. Vashisht, and T. Casale Omalizumab for treatment of allergic rhinitis Expert Opin Biol Ther 13 2013 933 945
29. C. Incorvaia, N. Fuiano, and G.W. Canonica Seeking allergy when it hides: which are the best fitting tests? World Allergy Organ J 6 2013 11
30. T.B. Casale, J. Condemi, and C. LaForce Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial JAMA 286 2001 2956 2967
31. E. Adelroth, S. Rak, and T. Haahtela Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis J Allergy Clin Immunol 106 2000 253 259
32. K. Okubo, S. Ogino, T. Nagakura, and T. Ishikawa Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis Allergol Int 55 2006 379 386
33. P. Chervinsky, T. Casale, and R. Townley Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis Ann Allergy Asthma Immunol 91 2003 160 167
34. A. Magnan, J.P. Meunier, C. Saugnac, J. Gasteau, and F. Neukirch Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study Allergy 63 2008 292 298
35. J. Bousquet, N. Khaltaev, and A.A. Cruz Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy 63 suppl 86 2008 8 160
36. A.M. Vignola, M. Humbert, and J. Bousquet Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR Allergy 59 2004 709 717
37. M. Humbert, L.P. Boulet, R.M. Niven, Z. Panahloo, M. Blogg, and G. Ayre Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis Allergy 64 2009 81 84
38. C.A. Akdis, C. Bachert, and C. Cingi Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology J Allergy Clin Immunol 131 2013 1479 1490
39. P. Gevaert, K.T. Nouri-Aria, and H. Wu Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps Allergy 68 2013 55 63
40. C. Bachert, P. Gevaert, G. Holtappels, S.G. Johansson, and P. van Cauwenberge Total and specific IgE in nasal polyps is related to local eosinophilic inflammation J Allergy Clin Immunol 107 2001 607 614
41. R. Penn, and S. Mikula The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study Am J Rhinol 21 2007 428 432
42. C. Vennera Mdel, C. Picado, J. Mullol, I. Alobid, and M. Bernal-Sprekelsen Efficacy of omalizumab in the treatment of nasal polyps Thorax 66 2011 824 825
43. M. Guglielmo, C. Gulotta, F. Mancini, M. Sacchi, and F. Tarantini Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab J Investig Allergol Clin Immunol 19 2009 158 159
44. T. Tajiri, H. Matsumoto, and H. Hiraumi Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma Ann Allergy Asthma Immunol 110 2013 387 388
45. J.M. Pinto, N. Mehta, M. DiTineo, J. Wang, F.M. Baroody, and R.M. Naclerio A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis Rhinology 48 2010 318 324
46. S.N. Bains, and M.A. Judson Allergic bronchopulmonary aspergillosis Clin Chest Med 33 2012 265 281
47. C.K. van der Ent, H. Hoekstra, and G.T. Rijkers Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody Thorax 62 2007 276 277
48. J.M. Zirbes, and C.E. Milla Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis Pediatr Pulmonol 43 2008 607 610
49. R. Wong, M. Wong, P.D. Robinson, and D.A. Fitzgerald Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis Paediatr Respir Rev 14 2013 22 24
50. F. Brinkmann, N. Schwerk, G. Hansen, and M. Ballmann Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis Allergy 65 2010 134 135
51. A. Kanu, and K. Patel Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab) Pediatr Pulmonol 43 2008 1249 1251
52. P. Lebecque, A. Leonard, M. Argaz, V. Godding, and C. Pilette Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis BMJ Case Rep 2009 PII:bcr07.2008.0379
53. M.K. Elmallah, L. Hendeles, R.G. Hamilton, C. Capen, and P.M. Schuler Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin E therapy (omalizumab) J Pediatr Pharmacol Ther 17 2012 88 92
54. Homma T, Kurokawa M, Matsukura S, Yamaguchi M, Adachi M. Anti-IgE therapy for allergic bronchopulmonary aspergillosis [published online ahead of print November 28, 2013]. J Microbiol Immunol Infect. PII: S1684-1182(13) 00197-7.
55. I. Sastre, J. Blanco, H. Mata, and F. García A case of allergic bronchopulmonary aspergillosis treated with omalizumab J Investig Allergol Clin Immunol 22 2012 145 147
56. J. Collins, G. Devos, G. Hudes, and D. Rosenstreich Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab J Asthma Allergy 5 2012 65 70
57. L.A. Pérez-de-Llano, M.C. Vennera, and A. Parra Effects of omalizumab in Aspergillus-associated airway disease Thorax 66 2011 539 540
58. I. Tillie-Leblond, P. Germaud, and C. Leroyer Allergic bronchopulmonary aspergillosis and omalizumab Allergy 66 2011 1254 1256
59. R.G. Slavin, C. Ferioli, S.J. Tannenbaum, C. Martin, M. Blogg, and P.J. Lowe Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations J Allergy Clin Immunol 123 2009 107 113.e3
60. P.J. Lowe, and D. Renard Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE Br J Clin Pharmacol 72 2011 306 320
61. T.B.1 Casale, I.L. Bernstein, W.W. Busse, C.F. LaForce, D.G. Tinkelman, R.R. Stoltz, R.J. Dockhorn, J. Reimann, J.Q. Su, R.B. Fick Jr., and D.C. Adelman Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis J Allergy Clin Immunol 100 1997 110 121
62. T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi, and T. Ishikawa Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis Clin Exp Allergy 38 2008 329 337